Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Willett CG, et al. Among authors: chen hx. Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25. Nat Med. 2004. PMID: 14745444 Free PMC article. Clinical Trial.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. Among authors: chen hx. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.
Are we ready for the 10% solution?
Chen HX, Rubinstein LV, Shankar LK, Abrams JS. Chen HX, et al. Oncologist. 2014 May;19(5):439-40. doi: 10.1634/theoncologist.2014-0126. Epub 2014 Apr 22. Oncologist. 2014. PMID: 24755462 Free PMC article.
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. Busaidy NL, et al. Among authors: chen hx. Oncologist. 2015 Jul;20(7):737-41. doi: 10.1634/theoncologist.2015-0065. Epub 2015 Jun 8. Oncologist. 2015. PMID: 26054632 Free PMC article. Clinical Trial.
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Saltz LB, et al. Among authors: chen hx. J Clin Oncol. 2007 Oct 10;25(29):4557-61. doi: 10.1200/JCO.2007.12.0949. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876013 Clinical Trial.
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ; Children's Oncology Group Study. Glade Bender JL, et al. Among authors: chen hx. J Clin Oncol. 2008 Jan 20;26(3):399-405. doi: 10.1200/JCO.2007.11.9230. J Clin Oncol. 2008. PMID: 18202416 Clinical Trial.
819 results